Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trialSun Young Rha, Xiaochun Zhang, Min‐Hee Ryu et al.|The Lancet Oncology|2023Cited by 614
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic CancerHedy L. Kindler, Talia Golan, Pascal Hammel et al.|Journal of Clinical Oncology|2022Cited by 224